At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...

Jan 8 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis ...

As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan 8 (Reuters) - Eli Lilly said on Thursday a late-stage trial showed ...

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater improvement in tender and swollen joints compared to those on Taltz alone, a new ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced Thursday that its Phase 3b TOGETHER-PsA trial met its primary endpoint, showing that concomitant use of Taltz (ixekizumab) and Zepbound ...

Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. Elaine Chen covers biotech, co-writes The Readout ...

Trade bodies representing the European prescription and over-the-counter pharma sectors have issued a call to action to regulators, asking them to accelerate the adoption of electronic product ...